scholarly journals Serum Hepatocyte Growth Factor Is Probably Associated With 3-Month Prognosis of Acute Ischemic Stroke

Stroke ◽  
2018 ◽  
Vol 49 (2) ◽  
pp. 377-383 ◽  
Author(s):  
Zhengbao Zhu ◽  
Tan Xu ◽  
Daoxia Guo ◽  
Xinfeng Huangfu ◽  
Chongke Zhong ◽  
...  
2021 ◽  
Vol 12 ◽  
Author(s):  
Fangfang Li ◽  
Ping Liu ◽  
Yuyou Huang ◽  
Lingzhi Li ◽  
Sijia Zhang ◽  
...  

Hepatocyte growth factor (HGF) is a potential prognostic factor for acute ischemic stroke (AIS). In this study, we sought to validate its earlier predictive accuracy within 24 h for first-ever AIS. Moreover, as HGF interacts with interleukins, their associations may lead to novel immunomodulatory therapeutic strategies. Patients with first-ever AIS (n = 202) within 24 h were recruited. Plasma HGF and related interleukin concentrations were measured by multiplex immunoassays. The primary and secondary outcomes were major disability (modified Rankin scale score ≥3) at 3 months after AIS and death, respectively. Elastic net regression was applied to screen variables associated with stroke outcome; binary multivariable logistic analysis was then used to explore the relationship between HGF level and stroke outcome. After multivariate adjustment, upregulated HGF levels were associated with an increased risk of the primary outcome (odds ratio, 7.606; 95% confidence interval, 3.090–18.726; p < 0.001). Adding HGF to conventional risk factors significantly improved the predictive power for unfavorable outcomes (continuous net reclassification improvement 37.13%, p < 0.001; integrated discrimination improvement 8.71%, p < 0.001). The area under the receiver operating characteristic curve value of the traditional model was 0.8896 and reached 0.9210 when HGF was introduced into the model. An elevated HGF level may also be a risk factor for mortality within 3 months poststroke. The HGF level was also positively correlated with IL-10 and IL-16 levels, and HGF before interaction with all interleukins was markedly negatively correlated with the lymphocyte/neutrophil ratio. HGF within 24 h may have prognostic potential for AIS. Our findings reinforce the link between HGF and interleukins.


2015 ◽  
Vol 35 (6) ◽  
pp. 1044-1053 ◽  
Author(s):  
Rafael E Chaparro ◽  
Miwa Izutsu ◽  
Toshihiro Sasaki ◽  
Huaxin Sheng ◽  
Yi Zheng ◽  
...  

Hepatocyte growth factor (HGF), efficacious in preclinical models of acute central nervous system injury, is burdened by administration of full-length proteins. A multiinstitutional consortium investigated the efficacy of BB3, a small molecule with HGF-like activity that crosses the blood-brain barrier in rodent focal ischemic stroke using Stroke Therapy Academic Industry Roundtable (STAIR) and Good Laboratory Practice guidelines. In rats, BB3, begun 6 hours after temporary middle cerebral artery occlusion (tMCAO) reperfusion, or permanent middle cerebral artery occlusion (pMCAO) onset, and continued for 14 days consistently improved long-term neurologic function independent of sex, age, or laboratory. BB3 had little effect on cerebral infarct size and no effect on blood pressure. BB3 increased HGF receptor c-Met phosphorylation and synaptophysin expression in penumbral tissue consistent with a neurorestorative mechanism from HGF-like activity. In mouse tMCAO, BB3 starting 10 minutes after reperfusion and continued for 14 days improved neurologic function that persisted for 8 weeks in some, but not all measures. Study in animals with comorbidities and those exposed to common stroke drugs are the next steps to complete preclinical assessment. These data, generated in independent, masked, and rigorously controlled settings, are the first to suggest that the HGF pathway can potentially be harnessed by BB3 for neurologic benefit after ischemic stroke.


Stroke ◽  
2010 ◽  
Vol 41 (5) ◽  
pp. 857-862 ◽  
Author(s):  
Swapnil N. Rajpathak ◽  
Tao Wang ◽  
Sylvia Wassertheil-Smoller ◽  
Howard D. Strickler ◽  
Robert C. Kaplan ◽  
...  

Pneumologie ◽  
2014 ◽  
Vol 68 (06) ◽  
Author(s):  
S Skwarna ◽  
I Henneke ◽  
W Seeger ◽  
T Geiser ◽  
A Günther ◽  
...  

Diabetes ◽  
1997 ◽  
Vol 46 (1) ◽  
pp. 138-142 ◽  
Author(s):  
R. Morishita ◽  
S. Nakamura ◽  
Y. Nakamura ◽  
M. Aoki ◽  
A. Moriguchi ◽  
...  

Diabetes ◽  
1998 ◽  
Vol 47 (1) ◽  
pp. 134-137 ◽  
Author(s):  
V. H. Lefebvre ◽  
T. Otonkoski ◽  
J. Ustinov ◽  
M. A. Huotari ◽  
D. G. Pipeleers ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document